Novel Antibody-Drug Conjugates Show Survival Benefit in Relapsed Small-Cell Lung Cancer
Source Summary
Two investigational anti-B7-H3 antibody-drug conjugates (ADCs) demonstrated significant improvements in survival outcomes for patients with relapsed small-cell lung cancer in Chinese clinical trials. The findings come from studies including the TAISHAN-302 trial.
Why it matters
These results represent a potential new treatment option for relapsed small-cell lung cancer, a disease with limited therapeutic alternatives.
